Opko Health (OPK) to Release Quarterly Earnings on Wednesday

Opko Health (NASDAQ:OPK) is scheduled to announce its earnings results after the market closes on Wednesday, August 7th. Analysts expect the company to announce earnings of ($0.11) per share for the quarter. Investors that wish to listen to the company’s conference call can do so using this link.

Opko Health (NASDAQ:OPK) last released its earnings results on Tuesday, May 7th. The biotechnology company reported ($0.14) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.06) by ($0.08). The firm had revenue of $222.50 million during the quarter, compared to the consensus estimate of $241.27 million. Opko Health had a negative return on equity of 9.86% and a negative net margin of 19.92%. The business’s quarterly revenue was down 12.7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.08) EPS. On average, analysts expect Opko Health to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

NASDAQ:OPK traded down $0.01 during mid-day trading on Tuesday, reaching $1.93. The stock had a trading volume of 66,983 shares, compared to its average volume of 3,312,057. The company has a 50 day moving average price of $2.14. The company has a market capitalization of $1.23 billion, a PE ratio of -7.70 and a beta of 2.15. Opko Health has a one year low of $1.73 and a one year high of $6.16. The company has a quick ratio of 0.99, a current ratio of 1.10 and a debt-to-equity ratio of 0.13.

In related news, Director Richard C. Pfenniger, Jr. purchased 30,000 shares of the firm’s stock in a transaction on Wednesday, May 22nd. The shares were acquired at an average cost of $2.05 per share, with a total value of $61,500.00. Following the purchase, the director now directly owns 250,000 shares of the company’s stock, valued at $512,500. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Phillip Md Et Al Frost purchased 50,000 shares of the firm’s stock in a transaction on Tuesday, July 16th. The stock was bought at an average cost of $2.12 per share, for a total transaction of $106,000.00. Following the completion of the purchase, the chief executive officer now directly owns 3,068,951 shares in the company, valued at $6,506,176.12. The disclosure for this purchase can be found here. Insiders purchased a total of 2,545,250 shares of company stock valued at $5,202,900 in the last 90 days. 42.25% of the stock is currently owned by corporate insiders.

A number of research firms recently weighed in on OPK. Zacks Investment Research upgraded Opko Health from a “hold” rating to a “buy” rating and set a $2.75 target price for the company in a research report on Tuesday, April 30th. ValuEngine upgraded Opko Health from a “sell” rating to a “hold” rating in a research report on Thursday, August 1st. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $9.25.

About Opko Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories, a clinical laboratory that offers laboratory testing services.

Further Reading: Total Return

Earnings History for Opko Health (NASDAQ:OPK)

Receive News & Ratings for Opko Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health and related companies with MarketBeat.com's FREE daily email newsletter.